Floatz logo

Iparomlimab

Metastatic Colorectal Cancer (CRC)

Jiangsu Cancer Institute & HospitalPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the Metastatic Colorectal Cancer (CRC) cohort.

Asset / SponsorPhaseRating
Tuvonralimab
Jiangsu Cancer Institute & Hospital
Phase 2B
trs003
Zhejiang Teruisi Pharmaceutical Inc.
Phase 3B
Immunoglobulin G4 [221-proline], anti-(human programmed cell death protein 1) (human monoclonal SG001 ?4-chain), disulfide with human monoclonal SG001 ?-chain, dimer
Hebei Medical University Fourth Hospital
Phase 2/3CCC
Ssgj-706
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2CCC
Nelmastobart
STCube, Inc.
Phase 1/2CC

View all 14 →

Same molecule, other indications

Iparomlimab is also rated in:

HCC - Hepatocellular CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
ES-SCLCDormant
BB
Indicative ·
70 / 100
View asset →
CTLA-4Dormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →